COVID-19感染与新发糖尿病的关联
这项基于人群的队列研究在加拿大不列颠哥伦比亚省2020年1月1日至2021年12月31日检测SARS-CoV-2者中,按1:4匹配暴露(阳性)与未暴露(阴性)人群,随访中位257天,评估感染后30天以上新发糖尿病风险。暴露组新发糖尿病发生率672.2/10万人年 vs 未暴露组508.7/10万人年(P<.001),校正HR 1.17(95%CI 1.06-1.28),男性aHR 1.22(95%CI 1.06-1.40)。重症感染者风险更高:ICU住院HR 3.29(95%CI 1.98-5.48),住院HR 2.42(95%CI 1.87-3.15)。归因于SARS-CoV-2感染的糖尿病比例总体3.41%(95%CI 1.20%-5.61%),男性4.75%(95%CI 1.30%-8.20%)。提示COVID-19可能造成3%-5%的额外糖尿病负担。
要点
- 暴露组新发糖尿病发生率672.2/10万人年 vs 未暴露组508.7/10万人年(P<.001)。
- 校正后SARS-CoV-2感染与新发糖尿病风险升高相关(HR 1.17;95%CI 1.06-1.28)。
- 男性感染者糖尿病风险升高(aHR 1.22;95%CI 1.06-1.40)。
- 重症感染者风险更高:ICU住院HR 3.29(95%CI 1.98-5.48),住院HR 2.42(95%CI 1.87-3.15)。
- 感染归因糖尿病比例总体3.41%(95%CI 1.20%-5.61%),男性4.75%(95%CI 1.30%-8.20%)。
适用人群与场景
- 加拿大不列颠哥伦比亚省2020年1月1日至2021年12月31日期间接受SARS-CoV-2 RT-PCR检测者。
- 暴露组:SARS-CoV-2检测阳性者;未暴露组:检测阴性者,按性别、年龄、RT-PCR采样日期1:4匹配。
- 分析样本629,935人,中位年龄32(IQR 25.0-42.0)岁,女性322,565人(51.2%)。
诊断标准与关键阈值
- 新发糖尿病定义为SARS-CoV-2检测采样日期后30天以上,基于就诊、住院记录、慢性病登记和糖尿病管理处方药验证算法识别(胰岛素依赖或非胰岛素依赖)。
研究设计与关键结果
- 研究类型:基于人群的队列研究,使用不列颠哥伦比亚省COVID-19队列,暴露组125,987人,未暴露组503,948人。
- 随访中位(IQR)257(102-356)天,暴露组新发糖尿病608例(0.5%),未暴露组1864例(0.4%)。
- 新发糖尿病发生率:暴露组672.2/10万人年(95%CI 618.7-725.6) vs 未暴露组508.7/10万人年(95%CI 485.6-531.8),P<.001。
- 暴露组新发糖尿病风险升高:HR 1.17(95%CI 1.06-1.28);男性aHR 1.22(95%CI 1.06-1.40)。
- 重症感染者风险更高:ICU住院HR 3.29(95%CI 1.98-5.48),住院HR 2.42(95%CI 1.87-3.15)。
- 归因于SARS-CoV-2感染的新发糖尿病比例总体3.41%(95%CI 1.20%-5.61%),男性4.75%(95%CI 1.30%-8.20%)。
证据类型、等级与局限
- 证据类型:基于人群的队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为SARS-CoV-2感染与糖尿病风险升高相关,并可能在人群层面造成3%至5%的额外糖尿病负担。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: SARS-CoV-2 infection may lead to acute and chronic sequelae. Emerging evidence suggests a higher risk of diabetes after infection, but population-based evidence is still sparse.
OBJECTIVE: To evaluate the association between COVID-19 infection, including severity of infection, and risk of diabetes.
DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study was conducted in British Columbia, Canada, from January 1, 2020, to December 31, 2021, using the British Columbia COVID-19 Cohort, a surveillance platform that integrates COVID-19 data with population-based registries and administrative data sets. Individuals tested for SARS-CoV-2 by real-time reverse transcription-polymerase chain reaction (RT-PCR) were included. Those who tested positive for SARS-CoV-2 (ie, those who were exposed) were matched on sex, age, and collection date of RT-PCR test at a 1:4 ratio to those who tested negative (ie, those who were unexposed). Analysis was conducted January 14, 2022, to January 19, 2023.
EXPOSURE: SARS-CoV-2 infection.
MAIN OUTCOMES AND MEASURES: The primary outcome was incident diabetes (insulin dependent or not insulin dependent) identified more than 30 days after the specimen collection date for the SARS-CoV-2 test with a validated algorithm based on medical visits, hospitalization records, chronic disease registry, and prescription drugs for diabetes management. Multivariable Cox proportional hazard modeling was performed to evaluate the association between SARS-CoV-2 infection and diabetes risk. Stratified analyses were performed to assess the interaction of SARS-CoV-2 infection with diabetes risk by sex, age, and vaccination status.
RESULTS: Among 629 935 individuals (median [IQR] age, 32 [25.0-42.0] years; 322 565 females [51.2%]) tested for SARS-CoV-2 in the analytic sample, 125 987 individuals were exposed and 503 948 individuals were unexposed. During the median (IQR) follow-up of 257 (102-356) days, events of incident diabetes were observed among 608 individuals who were exposed (0.5%) and 1864 individuals who were not exposed (0.4%). The incident diabetes rate per 100 000 person-years was significantly higher in the exposed vs nonexposed group (672.2 incidents; 95% CI, 618.7-725.6 incidents vs 508.7 incidents; 95% CI, 485.6-531.8 incidents; P < .001). The risk of incident diabetes was also higher in the exposed group (hazard ratio [HR], 1.17; 95% CI, 1.06-1.28) and among males (adjusted HR, 1.22; 95% CI, 1.06-1.40). The risk of diabetes was higher among people with severe disease vs those without COVID-19, including individuals admitted to the intensive care unit (HR, 3.29; 95% CI, 1.98-5.48) or hospital (HR, 2.42; 95% CI, 1.87-3.15). The fraction of incident diabetes cases attributable to SARS-CoV-2 infection was 3.41% (95% CI, 1.20%-5.61%) overall and 4.75% (95% CI, 1.30%-8.20%) among males.
CONCLUSIONS AND RELEVANCE: In this cohort study, SARS-CoV-2 infection was associated with a higher risk of diabetes and may have contributed to a 3% to 5% excess burden of diabetes at a population level.
参考来源
- Naveed Z, Velásquez García HA, Wong S, et al. Association of COVID-19 Infection With Incident Diabetes. JAMA Netw Open. 2023. PMID: 37071420. doi:10.1001/jamanetworkopen.2023.8866
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。